{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:11:43Z","timestamp":1788901903246,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","award":["2023xkj130"],"award-info":[{"award-number":["2023xkj130"]}],"id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hepatobiliary & Pancreatic Diseases International"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.hbpd.2026.08.008","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:47:46Z","timestamp":1787849266000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic signatures in metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma"],"prefix":"10.1016","author":[{"given":"Wen-Jie","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Mei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Ao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hbpd.2026.08.008_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103910","article-title":"NAFLD and NASH: etiology, targets and emerging therapies","volume":"29","author":"Wei","year":"2024","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0002","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s12072-024-10692-4","article-title":"Epidemiology, pathophysiology and clinical aspects of hepatocellular carcinoma in MAFLD patients","volume":"18","author":"Argenziano","year":"2024","journal-title":"Hepatol Int"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0003","doi-asserted-by":"crossref","first-page":"7083","DOI":"10.1038\/s41598-025-91312-5","article-title":"Global burden of MAFLD, MAFLD related cirrhosis and MASH related liver cancer from 1990 to 2021","volume":"15","author":"Guo","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0004","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0005","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cgh.2012.10.001","article-title":"Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review","volume":"10","author":"White","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0006","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/jgh.16922","article-title":"Metabolic cause of cirrhosis is the emerging etiology for primary liver cancer in the Asia-Oceania region: analysis of Global Burden of Disease (GBD) study 2021","volume":"40","author":"Giri","year":"2025","journal-title":"J Gastro And Hepatol"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0007","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/hep.29276","article-title":"Loss of l-selectin-guided CD8+, but not CD4+, cells protects against ischemia reperfusion injury in a steatotic liver","volume":"66","author":"Kolachala","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0008","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/hep.30401","article-title":"Dietary lipids differentially shape nonalcoholic steatohepatitis progression and the transcriptome of kupffer cells and infiltrating macrophages","volume":"70","author":"McGettigan","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0009","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/apt.15464","article-title":"Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study","volume":"50","author":"Gawrieh","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0010","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(22)00078-X","article-title":"Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis","volume":"23","author":"Tan","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0011","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/gutjnl-2020-321702","article-title":"Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups","volume":"70","author":"Pinter","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0012","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jhep.2019.08.025","article-title":"Epidemiology and surveillance for hepatocellular carcinoma: new trends","volume":"72","author":"Singal","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0013","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1111\/cas.15925","article-title":"Clinico-histological and molecular features of hepatocellular carcinoma from nonalcoholic fatty liver disease","volume":"114","author":"Fujiwara","year":"2023","journal-title":"Cancer Sci"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0014","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/ncb3629","article-title":"The impact of cellular metabolism on chromatin dynamics and epigenetics","volume":"19","author":"Reid","year":"2017","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0015","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.3390\/cancers14246234","article-title":"Metabolic risk factors for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a prospective study","volume":"14","author":"Antwi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0016","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-18197-6","article-title":"Correlation analysis of metabolic characteristics and the risk of metabolic-associated fatty liver disease - related hepatocellular carcinoma","volume":"12","author":"Xie","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0017","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8813410","article-title":"Metabolic alteration in hepatocellular carcinoma: mechanism of lipid accumulation in well-differentiated hepatocellular carcinoma","volume":"2021","author":"Suzuki","year":"2021","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0018","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/metabo11010054","article-title":"Two metabolomics phenotypes of human hepatocellular carcinoma in non-alcoholic fatty liver disease according to fibrosis severity","volume":"11","author":"Buchard","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0019","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.3390\/ijms21207746","article-title":"Accumulation of 8-hydroxydeoxyguanosine, l-arginine and glucose metabolites by liver tumor cells are the important characteristic features of metabolic syndrome and non-alcoholic steatohepatitis-associated hepatocarcinogenesis","volume":"21","author":"Kakehashi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0020","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1136\/gutjnl-2017-315193","article-title":"CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity","volume":"67","author":"Fujiwara","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0021","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.cmet.2009.02.006","article-title":"Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation","volume":"9","author":"Purushotham","year":"2009","journal-title":"Cell Metab"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0022","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12943-024-02119-3","article-title":"Altered metabolism in cancer: insights into energy pathways and therapeutic targets","volume":"23","author":"Tufail","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103661","article-title":"The altered serum lipidome and its diagnostic potential for non-alcoholic fatty liver (NAFL)-associated hepatocellular carcinoma","volume":"73","author":"Lewinska","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0024","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1158\/0008-5472.CAN-12-3797","article-title":"Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma","volume":"73","author":"Muir","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0025","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/hep.31391","article-title":"Lipid remodeling in hepatocyte proliferation and hepatocellular carcinoma","volume":"73","author":"Hall","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0026","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrm.2017.107","article-title":"Sphingolipids and their metabolism in physiology and disease","volume":"19","author":"Hannun","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0027","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/ijms21010040","article-title":"Sphingolipids in non-alcoholic fatty liver disease and hepatocellular carcinoma: ceramide turnover","volume":"21","author":"Simon","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0028","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1021\/acscentsci.7b00582","article-title":"A ceramide-regulated element in the late endosomal protein LAPTM4B controls amino acid transporter interaction","volume":"4","author":"Zhou","year":"2018","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0029","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/bs.acr.2018.05.002","article-title":"Sphingolipids at the crossroads of MASLD and senescence","volume":"140","author":"Nikolova-Karakashian","year":"2018","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0030","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/ijms24010210","article-title":"Metabolomics and lipidomics screening reveal reprogrammed signaling pathways toward cancer development in non-alcoholic steatohepatitis","volume":"24","author":"Ahmed","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0031","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/gutjnl-2019-319664","article-title":"Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites","volume":"70","author":"Zhang","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0032","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jhep.2021.01.028","article-title":"STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway","volume":"74","author":"Conde de la Rosa","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0033","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/gutjnl-2015-310283","article-title":"Microbiota-induced obesity requires farnesoid X receptor","volume":"66","author":"Pars\u00e9us","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0034","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jhep.2021.04.049","article-title":"Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis","volume":"75","author":"Pinyol","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0035","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ccell.2016.10.007","article-title":"Circadian homeostasis of liver metabolism suppresses hepatocarcinogenesis","volume":"30","author":"Kettner","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0036","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/ijc.30219","article-title":"Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis","volume":"139","author":"Xie","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0037","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000131","article-title":"Altered microbiota diversity and bile acid signaling in cirrhotic and noncirrhotic NASH-HCC","volume":"11","author":"Sydor","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0038","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nature12347","article-title":"Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome","volume":"499","author":"Yoshimoto","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114497","article-title":"Activation of FXR modulates SOCS3\/Jak2\/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model","volume":"186","author":"Attia","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0040","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/metabo7040049","article-title":"Specificities of human hepatocellular carcinoma developed on non-alcoholic fatty liver disease in absence of cirrhosis revealed by tissue extracts 1H-NMR spectroscopy","volume":"7","author":"Teilhet","year":"2017","journal-title":"Metabolites"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0041","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41575-019-0217-8","article-title":"Metabolic rearrangements in primary liver cancers: cause and consequences","volume":"16","author":"Satriano","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0042","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/hep.21531","article-title":"Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis","volume":"45","author":"Di Tommaso","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0043","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.cmet.2018.12.020","article-title":"Loss of BCAA catabolism during carcinogenesis enhances mTORC1 activity and promotes tumor development and progression","volume":"29","author":"Ericksen","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0044","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1097\/HEP.0000000000000420","article-title":"Purine anabolism creates therapeutic vulnerability in hepatocellular carcinoma through m6A-mediated epitranscriptomic regulation","volume":"78","author":"Hung","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0045","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/hep.26929","article-title":"Ribonucleotide reductase M2B inhibits cell migration and spreading by early growth response protein 1-mediated phosphatase and tensin homolog\/Akt1 pathway in hepatocellular carcinoma","volume":"59","author":"Tian","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0046","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s13105-024-01061-8","article-title":"Prognostic model development using novel genetic signature associated with adenosine metabolism and immune status for patients with hepatocellular carcinoma","volume":"81","author":"Chen","year":"2025","journal-title":"J Physiol Biochem"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0047","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hep.31685","article-title":"Targeting the de novo purine synthesis pathway through adenylosuccinate lyase depletion impairs liver cancer growth by perturbing mitochondrial function","volume":"74","author":"Jiang","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0048","doi-asserted-by":"crossref","first-page":"5881","DOI":"10.1158\/1078-0432.CCR-17-1151","article-title":"MUC1-mediated metabolic alterations regulate response to radiotherapy in pancreatic cancer","volume":"23","author":"Gunda","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0049","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3390\/metabo13111116","article-title":"A nucleotide metabolism-related gene signature for risk stratification and prognosis prediction in hepatocellular carcinoma based on an integrated transcriptomics and metabolomics approach","volume":"13","author":"Wei","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0050","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.devcel.2022.06.003","article-title":"Replication stress triggered by nucleotide pool imbalance drives DNA damage and cGAS-STING pathway activation in NAFLD","volume":"57","author":"Donne","year":"2022","journal-title":"Dev Cell"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0051","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jhep.2023.02.033","article-title":"Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation","volume":"79","author":"Yahoo","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0052","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"European association for the study of the liver. EASL clinical practice guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0053","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","volume":"74","author":"Bianco","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0054","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/hep.31238","article-title":"Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population","volume":"72","author":"Gellert-Kristensen","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0055","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jhep.2021.09.007","article-title":"NAFLD-driven HCC: safety and efficacy of current and emerging treatment options","volume":"76","author":"Foerster","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0056","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccell.2024.01.007","article-title":"Precision treatment in advanced hepatocellular carcinoma","volume":"42","author":"Yang","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100330","article-title":"Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib","volume":"6","author":"Rimini","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0058","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0059","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.jhep.2023.04.012","article-title":"Aetiology of liver disease and response to immune checkpoint inhibitors: an updated meta-analysis confirms benefit in those with non-viral liver disease","volume":"79","author":"Meyer","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0060","article-title":"METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy","volume":"4","author":"Pan","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107375","article-title":"NAFLD-associated hepatocellular carcinoma (HCC)-A compelling case for repositioning of existing mTORc1 inhibitors","volume":"208","author":"Sharma","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.hbpd.2026.08.008_bib0062","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cmet.2014.05.001","article-title":"Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition","volume":"20","author":"Umemura","year":"2014","journal-title":"Cell Metab"}],"container-title":["Hepatobiliary & Pancreatic Diseases International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S149938722600130X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S149938722600130X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:49:24Z","timestamp":1788900564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S149938722600130X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":62,"alternative-id":["S149938722600130X"],"URL":"https:\/\/doi.org\/10.1016\/j.hbpd.2026.08.008","relation":{},"ISSN":["1499-3872"],"issn-type":[{"value":"1499-3872","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic signatures in metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Hepatobiliary & Pancreatic Diseases International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hbpd.2026.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}